<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9EC955A9-7A7E-434C-BBD8-CE3B521C2821"><gtr:id>9EC955A9-7A7E-434C-BBD8-CE3B521C2821</gtr:id><gtr:name>University of Alberta</gtr:name><gtr:address><gtr:line1>University of Alberta</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9EC955A9-7A7E-434C-BBD8-CE3B521C2821"><gtr:id>9EC955A9-7A7E-434C-BBD8-CE3B521C2821</gtr:id><gtr:name>University of Alberta</gtr:name><gtr:address><gtr:line1>University of Alberta</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/39EE3945-CDA5-4319-8051-46B34D3B9AA0"><gtr:id>39EE3945-CDA5-4319-8051-46B34D3B9AA0</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Ferguson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G0900864"><gtr:id>25805404-5131-4265-B7C5-EA8710E5783D</gtr:id><gtr:title>DPFS Devolved Portfolio (Pilot)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G0900864</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>This is an award of a devolved portfolio under a pilot phase, as part of the implementation of the Development Pathway Funding Scheme (DPFS). DPFS Devolved Portfolios are block awards for specific universities to support goal-orientated translational research projects. The award allows universities to allocate the money to different translational projects more responsively based on their relative progress. For example the university might decide to stop a particular project and recycle the money allocated to it into other proposals. All projects supported by the Portfolio fall within the remit of the Development Pathway Funding Scheme (DPFS).</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2000000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Open innovation (AZ-OGA)</gtr:description><gtr:id>37132A28-C201-43FB-964C-8D226944E113</gtr:id><gtr:impact>Project in early stages and no outputs generated to date.</gtr:impact><gtr:outcomeId>56bc621008a623.34027179-1</gtr:outcomeId><gtr:partnerContribution>AZ will provide access to AZ screening facilities and will provide access to proprietary compound libraries.</gtr:partnerContribution><gtr:piContribution>The University of Dundee will use their OGA assay platform to screen the AZ compound libraries in order to identify new classes of OGA inhibitor. If suitable compounds are identified The University of Dundee will conduct structural biology, Medicinal chemistry and associated drug discovery activities to develop the hit compounds toward in vivo leads.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Discovery Partnership (HD)</gtr:description><gtr:id>6BC1BB22-1C6B-40EC-B56C-36A5359D51E8</gtr:id><gtr:impact>Milestones were all achieved. Lead optimisation halted due to lack of conclusive cellular data.</gtr:impact><gtr:outcomeId>dC4y9iFyZkD-1</gtr:outcomeId><gtr:partnerContribution>Drug discovery -compound design and screening.</gtr:partnerContribution><gtr:piContribution>Provide biology and assay expertise for drug discovery.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Alberta</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Cancer follow on study</gtr:description><gtr:id>F4995252-BE80-46B2-A94F-ECAD69F4C730</gtr:id><gtr:impact>Publications and two grant applications in progress.</gtr:impact><gtr:outcomeId>abbrWXJTUc9-1</gtr:outcomeId><gtr:partnerContribution>Broadening observations into other cancer types.</gtr:partnerContribution><gtr:piContribution>Supply of compounds and data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Discovery Partnerships with Academia</gtr:department><gtr:description>Discovery Partnership ( RT)</gtr:description><gtr:id>7FD1C380-DED6-4B4C-8FD8-D521FEFABD96</gtr:id><gtr:impact>Project closed due to failure to meet key milestone. IP around lead compounds developed during the colaboration was assigned to Dundee along with associated data. Details are confidential. Project has become the subject of a second commercial partnership (with the company Pfizer in this case). Discussed as a separate output.</gtr:impact><gtr:outcomeId>W46c3jddwSJ-1</gtr:outcomeId><gtr:partnerContribution>GSK are leading the drug discovery project, providing funding (for both Dundee nad GSK activities), expertise and access to equipment and models.</gtr:partnerContribution><gtr:piContribution>University of Dundee licenced the IP around the chemistry and biology debveloped in under MRC-DPFS funding. The University of Dundee team (The Drug Discovery Unit and Prof Irwin McLean's group) are providing biology and chemistry expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Fragment screening</gtr:description><gtr:id>BE6B7F27-AD06-4F8D-B5CB-B034003CE538</gtr:id><gtr:impact>Manuscript in preparation.</gtr:impact><gtr:outcomeId>CgxM3Kc2U19-1</gtr:outcomeId><gtr:partnerContribution>Provided target.</gtr:partnerContribution><gtr:piContribution>Conducted screen.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CRUK screen NRF2</gtr:description><gtr:id>BCFDB1D5-6390-4538-BF3B-5B73DA18B3C1</gtr:id><gtr:impact>Too early</gtr:impact><gtr:outcomeId>56d45ef59630f3.08818108-1</gtr:outcomeId><gtr:partnerContribution>Compound library screening and follow on drug discovery resource and expertise</gtr:partnerContribution><gtr:piContribution>Expertise and specialist systems for the investigation of NRF2 biology</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Orphan &amp; Genetic Diseases Research Unit Pfizer</gtr:department><gtr:description>Drug Discovery partnership (Pfizer-RT project)</gtr:description><gtr:id>12710153-0011-4655-B517-F37B4AEEC90B</gtr:id><gtr:impact>Projects status is confidential</gtr:impact><gtr:outcomeId>56bc4928eecec1.58655776-1</gtr:outcomeId><gtr:partnerContribution>In addition to fully funding University of Dundee activities, Pfizer are providing access to compound libraries, models and drug discovery expertise. The project is part of the Pfizer-RDRU, with Pfizer staff members providing Project management and technical expertise to the project.</gtr:partnerContribution><gtr:piContribution>The University of Dundee licenced the background IP around the projects chemical matter and biological model systems. The University of Dundee team are developing assays and support for high-throughput screening. The majority of the projects biology work is conducted by the Dundee team. The Dundee team are also providing Medicinal Chemistry and Project management expertise for the project.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Imaging of echogenic microbubbles and liposomes</gtr:description><gtr:id>406FCDB6-0695-4AED-84E7-E642760CAC08</gtr:id><gtr:impact>Results leading to possible future collaboration. Multidisciplinary-physics, chemistry, biology.</gtr:impact><gtr:outcomeId>A2XQA7EUexu-1</gtr:outcomeId><gtr:partnerContribution>Testing of equipment and development of software and hardware</gtr:partnerContribution><gtr:piContribution>Development of equipment and imaging protocols</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open Doors Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>800FCB44-2544-4521-9A25-F2A6D3D65CFD</gtr:id><gtr:impact>General public attended .

Raise awareness of science being done at College of Life Sciences, University of Dundee via exhibits and workshops.</gtr:impact><gtr:outcomeId>ef7Yxy99FNZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference proceedings (AM 2014)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7763FF5B-2A5F-4450-91AB-6A5508647E5E</gtr:id><gtr:impact>Cox BF, Eisma R, Rube MA, Immel E, Gueorguieva M, McLeod H, Melzer A. Developing Thiel Soft-Fix Cadavers as a suitable model for iMRI training and research. Abstract, Presented at the 9th International Interventional MRI Symposium, September, 2012. 

Pendleton M, Cox BF, Saliev T, Rube MA, McLeod H, Melzer A. Imaging of Vessel Patency in Thiel Embalmed Liver. Oral Presentation, Presented at Fifth Image Guided Therapy Workshop of the National Center for Image-Guided Therapy, September, 2012. 

Cox BF, McLeod H, Rube MA, Vinnicombe S, Holbrook AB, Eisma R, Saliev T, Karakitsios I, Melzer A. MR real-time tracking of hepatic motion during respiration in a Thiel Soft-fix cadaver. Oral Presentation, Presented at the 46th Annual Conference of the Deutsche Gesellschaft f&amp;uuml;r Biomedizinische Technik, September 2012.

Rube MA, Immel E, Cox B, Melzer A. Towards Interventional MRI: Semi-Active Device Localization in Phantom Experiments and in a Thiel Embalmed Human Cadaver Model. Oral Presentation, Presented at the 26th International Congress and Exhibition of Computer Assisted Radiology and Surgery, June 2012.

McLeod H, Cox B, Eisma R, Mathew S, Melzer A, Houston G. Thiel Embalmed Human Cadaver: Vascular Model Development for Teaching and Training. Poster session presented: College Research Symposium, University of Dundee, Crieff, Feb 20th - 21st 2014. 

McLeod H, Cox B, Eisma R, Immel E, Roberston J, Melzer A, Houston G. Thiel Embalmed Human Cadaver: Venous Modeling. Poster Session presented at 26th Society for Medical Innovaton and Technology, Shanghai, 18- 21st Sept 2014. 

McLeod H, Cox B, Eisma R, Immel E, Pendleton M, Melzer A, Houston G. Thiel Embalmed Human Cadaver: Extracorporeal Central Arterial Circulatory Model Development. Oral Presentation presented at 26th Society for Medical Innovaton and Technology, Shanghai, 18- 21st Sept 2014. 


Continuation of the demonstration of the strengths of this relatively new technology area amongst the academic community and those responsible for future clinical training and practice.</gtr:impact><gtr:outcomeId>54632cb487f3f3.30221240</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to GP's</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5AEC58C8-D9ED-436A-AA99-E191FAE236E9</gtr:id><gtr:impact>Talk sparked questions and discussion.

It is anticipated that there will be better informed treatment decisions as a result of the talk . The talk was only delivered on 28th October 2014 and as such feedback is expected over the next few months.</gtr:impact><gtr:outcomeId>545ce6ea9d55d7.93522216</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference proceedings (AM/2013)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>37152878-922C-4217-9DCB-7A198F9CD17C</gtr:id><gtr:impact>Invited session and Chair at CARS 2013
Organised the 2nd Eurpoean FUS Therapy Symposium Rome 10-11th October 2013

Demonstration that this relatively newtechnology has lead to increased collbaorative opportunities and uptake of the technology that will impact on future clinical training and practice.</gtr:impact><gtr:outcomeId>qiJpTZ4tTok</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference proceedings (AM group)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CC638048-A1D1-45FD-8501-D889C46F3203</gtr:id><gtr:impact>Gueorguieva M., Yeo D., Eisma R. and Melzer A., (2012). MR Imaging of Thiel embalmed human cadavers. 20th Annual meeting of the International Society for Magnetic Resonance in Medicine, ISMRM, Melbourne, Australia 
? Rube M., Kokkalis E., Immel E., Gueorguieva M., Eisma R. And Melzer A., (2012). Training and Testing Environment for MR-guided Vascular Interventions. 20th Annual meeting of the International Society for Magnetic Resonance in Medicine, ISMRM, Melbourne, Australia
? Eisma R., Gueorguieva M., Immel E., Toomey R., Soames R., and Melzer A., (2012). Thiel embalmed cadavers as a model for research and training in minimally invasive therapies - a study of respiratory liver displacement. Joint Winter Meeting of Anatomical Societies, Dec. 2011 , Cardiff, UK. To be published in Journal of Anatomy.
? Toomey R.J., Gueorguieva M, Immel E, Houston J.G., McLeod G.A., Eisma R., Melzer A. (2011). Value and Techniques of Multi-Modality Imaging of Thiel Soft-Embalmed Cadavers for Research, Training and Device Development (Educational Exhibit). 97th Annual Meeting of the Radiological Society of North America, RSNA, Chicago, Illinois, USA
? Gueorguieva M. J., Immel E, Eisma R, and Melzer A., (2010). Improvement of MR Imaging of Thiel Embalmed Human Cadavers (Abstract). Minimally Invasive Therapy &amp;amp; Allied Technologies, MITAT, Vol. 19, Supplement 1: 40-41
? Immel E., Eisma R., Gueorguieva M., Fernandez-Gutierrez F., Houston G., and Melzer A., (2010). Comparison of X-Ray and MRI guided Implantation of a Resonant Balloon Expandable Stent in a Thiel Embalmed Cadaver (Abstract). Minimally Invasive Therapy &amp;amp; Allied Technologies, MITAT, Vol. 19, Supplement 1: 22-23
? Immel E., Eisma R., Gueorguieva M., Fernandez F., Houston G., and Melzer A., (2010). MRI guided Implantation of a Resonant Vena Cava Filter in a Thiel Embalmed Cadaver (Abstract). Minimally Invasive Therapy &amp;amp; Allied Technologies, MITAT, Vol. 19, Supplement 1: 50-51
&amp;quot; Thiel soft-fix embalming: the new face of anatomy in Dundee&amp;quot; Roos Eisma, presented at the Institute for Anatomical Sciences Autumn Scientific Meeting, St Andrews, 31 August 2012 and at the Association of Anatomical Pathology Technicians Conference, Bristol, 22 September 2012


Demonstrate utility of this relatively new technology area amongst the academic community.This will lead to increased collaborative opportunities and uptake of the technology that will impact on future clinical training and practice.</gtr:impact><gtr:outcomeId>PhmkJbovYP1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>282826</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Pathway Funding Scheme</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>514C208D-E085-4404-A7E3-023A1D9021EB</gtr:id><gtr:outcomeId>azB5egJSP620</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>454600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Healthcare Technology Challenges for Engineering</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K020013/1</gtr:fundingRef><gtr:id>53C7C964-91B5-46B4-859A-21900CA14E35</gtr:id><gtr:outcomeId>PG3vjjZ2847</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>13557</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chemistry Catalyst Fund</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>4FBABA6A-54DB-4002-9F1E-E266AE609AB9</gtr:id><gtr:outcomeId>B6WfbzE74qr0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>275000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Institutional Strategic Support Fund Y2</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>4D6D606A-CDCA-424A-9FA8-070A55CFE4FF</gtr:id><gtr:outcomeId>KkfTB1tunmG</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Tenovus Scotland</gtr:fundingOrg><gtr:id>EF2E05F5-ADC3-4E77-A41D-20E3C7DC14EA</gtr:id><gtr:outcomeId>56d86848f34322.44007622</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9640</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Drug discovery</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Tenovus Scotland</gtr:fundingOrg><gtr:id>DC7CC916-0FB9-47DB-86D7-6974419F61B1</gtr:id><gtr:outcomeId>BgNYAwBCaoB</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1670000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Strategic Award (DGEM)</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>7128575A-D173-4EDD-A37A-2E1AEFBE2F87</gtr:id><gtr:outcomeId>5461f9671d2027.95415154</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical device</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Dr Hadwen Trust (DHT)</gtr:fundingOrg><gtr:id>C2FB29D8-F9EF-4CD9-8B6D-627B7673440F</gtr:id><gtr:outcomeId>ndx5iwe7kjo</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept 2012</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DD5E9D33-BE76-48EA-9AB9-840C30C30436</gtr:id><gtr:outcomeId>o1qvN3GEPmz</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Darwin Trust of Edinburgh</gtr:department><gtr:description>Darwin Trust bequest</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>British Society for the History of Science (BSHS)</gtr:fundingOrg><gtr:id>5B6C649A-AF54-4A77-8E37-9FBDEAE319E9</gtr:id><gtr:outcomeId>544a495eef2737.07124833</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept 2014</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MC_PC_14099</gtr:fundingRef><gtr:id>7B6EAF1D-4CFB-4134-934D-59CC75FE67B4</gtr:id><gtr:outcomeId>56bc6603437003.50844599</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>418900</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>The Mary Lyon Centre</gtr:department><gtr:description>MRC Project Grant</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/KO13343/1</gtr:fundingRef><gtr:id>B859D790-A76F-4ABB-ACE6-3D53855639F3</gtr:id><gtr:outcomeId>AewTfW4N6Zq</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Innovative Medicines Initiative (IMI)</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>C2AB073F-7A48-42D9-AAE7-54017716A0CD</gtr:id><gtr:outcomeId>HiyJ1Pm7TCx</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>275000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Institutional Strategic Support Fund Y3</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>BF913CA4-73B9-4F59-812C-F558C8D39CA8</gtr:id><gtr:outcomeId>KgmewTDUze1</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>550000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Institutional Strategic Support Fund</gtr:department><gtr:description>Institutional Strategic Support Fund Y4-5</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>DBC592E6-4AED-49B0-B1A8-52E89A0C2EA4</gtr:id><gtr:outcomeId>544a4920864236.63588897</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>873623</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EC FP7 Cooperation</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>5160F2ED-7DE0-4E16-ACAF-90DF77FF7FE6</gtr:id><gtr:outcomeId>FYGHoGrne53</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>614248</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EC FP7 Cooperation</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>C9389E49-DB7C-486E-9C87-F1FCF6CC22B1</gtr:id><gtr:outcomeId>gPUzfqVVZpS</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1388746</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK programme grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C303/A14301</gtr:fundingRef><gtr:id>138CB825-25E1-4D42-AA13-D63A603B3010</gtr:id><gtr:outcomeId>56c1b16d7772a5.67101155</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chemistry Catalyst Fund</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>91477274-FECE-4F1C-8551-85A57C33958F</gtr:id><gtr:outcomeId>HCNeu5wuWY80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>924870</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Healthcare Technology Challenges for Engineering</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K020250/1</gtr:fundingRef><gtr:id>5A679ED1-DFAC-48F4-9D50-FF27980A88A0</gtr:id><gtr:outcomeId>RwU8DwF9Dp5</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>92173</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE studentship</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/JO11770/1</gtr:fundingRef><gtr:id>F57B2CBD-2BE3-4B82-A5E2-1DF4D4C598A1</gtr:id><gtr:outcomeId>54621d9075a248.96263050</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>148000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NRS NHS Research Fellowh</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>NHS Research Scotland</gtr:fundingOrg><gtr:id>BC40F5E0-7A60-472B-ACCA-23C86DE16227</gtr:id><gtr:outcomeId>YQp5uPTYysX</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept 2013</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MC_PC_13061</gtr:fundingRef><gtr:id>106863C8-4B1D-4659-B91A-8E781770C707</gtr:id><gtr:outcomeId>544a3356615951.05899047</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>275000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Institutional Strategic Support Fund</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>EB38E229-D6E0-4170-99B9-935B2EB494F1</gtr:id><gtr:outcomeId>Ga6cCr6eJu2</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15861</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chemistry Catalyst Fund</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>9C4A8274-015C-44B7-B533-8A24E228428E</gtr:id><gtr:outcomeId>q79TgC4gPAZ0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18897</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chemistry Catalyst Fund</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>306CA57F-0C32-4FE2-A162-42E042B22E5A</gtr:id><gtr:outcomeId>DbvNAAaEzEx0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Innovative therapeutics</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Charles Wolfson Charitable Trust</gtr:fundingOrg><gtr:id>11764E8B-514B-453E-85A8-6149A77BBA57</gtr:id><gtr:outcomeId>GCHUvn3PeWH</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Repositioning of known compounds and discovery of novel compounds for increasing sperm motility.</gtr:description><gtr:grantRef>MC_G0900864</gtr:grantRef><gtr:id>FA33D28D-A2C8-4EAC-8F19-14F8AAAEB984</gtr:id><gtr:impact>Ongoing drug discovery programmes.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>ZKBSwRk3Max</gtr:outcomeId><gtr:patentId>WO2013054111</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Modulators of cAMP-PDE</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Compounds with potential for therapy in neglected diseases and cancer. The MRC funded devolved portfolio funded a project in the cancer therapeutic area.</gtr:description><gtr:grantRef>MC_G0900864</gtr:grantRef><gtr:id>8F1F9087-E1FD-456F-8BEA-147C761106D5</gtr:id><gtr:impact>Collaboration with an international group.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>Ht9tHG4uqJb</gtr:outcomeId><gtr:patentId>EP2323987</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>NMT inhibitors</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A means of displacing internal organs to prevent them from obstructing a minimal access surgical procedure.</gtr:description><gtr:grantRef>MC_G0900864</gtr:grantRef><gtr:id>69782B18-AE4B-446A-BA73-446D0A9A860D</gtr:id><gtr:impact>None other than licence</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>qnWbaemdJGG</gtr:outcomeId><gtr:patentId>GB1100902.4</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Surgical tissue anchor</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRI guided DBS and Targeted Drug Delivery (www.IGI-TDD.eu)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>1B7D874C-B4D5-4D3D-9A02-037AFB2DEEC3</gtr:id><gtr:outcomeId>jh8pK6aSEcp</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.IGI-TDD.eu</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Cohort of psoriasis patients for genetic research</gtr:description><gtr:id>375A9C22-DCEB-459D-A17A-A3C80AEF0BFE</gtr:id><gtr:impact>Cohort under development . It will used to perform pharmacogenomic profiling for treatment effects.</gtr:impact><gtr:outcomeId>545ce80558c445.73976329</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Psoriasis cohort</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Madrasin is a highly characterised small molecule modulator of alternative splicing.</gtr:description><gtr:id>983C8FA8-422C-48C5-B600-38F4C80EB1FE</gtr:id><gtr:impact>The splicing field has been hapmered by the lack of a robust chemical tool to study the biology. Madrasin appears to fit the requirements of the community with multipe groups able to recapitulate its effects. The paper describing the discovery and characterisation of Madrasin has been cited 9 times to date.</gtr:impact><gtr:outcomeId>56bc4bc33609a0.42862623</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Madrasin</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.sigmaaldrich.com/catalog/product/sigma/sml1409?lang=en&amp;region=GB</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Use of established methodology for new use.</gtr:description><gtr:id>645D6B72-9BD9-40AF-B46C-6000B1736959</gtr:id><gtr:impact>Publication, new collaboration and funding leveraged.</gtr:impact><gtr:outcomeId>dvXCfbxXJwd</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GPCR Ligand screen</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New tool for development of workflow of MR guided vascular interventons and validation of MRI guided Focused Ultrsound on moving organs in perfused Thiel embalmed cadavers.</gtr:description><gtr:id>BD831B52-563E-4428-A073-23A6B65DA410</gtr:id><gtr:impact>Better model for vascular interventions and Focused Ultrasound of Moving Organs provides an alternative to animal models.</gtr:impact><gtr:outcomeId>ZSLyL1EUDxZ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MR-guided procedure</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>80B869A5-797B-4290-9FF7-69C35B92BB71</gtr:id><gtr:title>Liver displacement during ventilation in Thiel embalmed human cadavers - a possible model for research and training in minimally invasive therapies.</gtr:title><gtr:parentPublicationTitle>Minimally invasive therapy &amp; allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a08ba64f7f32a2eb1fce02a0ab9271bf"><gtr:id>a08ba64f7f32a2eb1fce02a0ab9271bf</gtr:id><gtr:otherNames>Eisma R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1364-5706</gtr:issn><gtr:outcomeId>pm_14237_27_23527683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F2DB7E2-F52E-4D17-B6AC-C2022D857C1E</gtr:id><gtr:title>Screening for GPCR Ligands Using Surface Plasmon Resonance.</gtr:title><gtr:parentPublicationTitle>ACS medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1cac3183a5a2f1554511ecfdd1e696e1"><gtr:id>1cac3183a5a2f1554511ecfdd1e696e1</gtr:id><gtr:otherNames>Navratilova I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1948-5875</gtr:issn><gtr:outcomeId>XBa1hhR7t1i</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>694808E5-C982-4848-A065-8C2F8FED4408</gtr:id><gtr:title>Clinically relevant enhancement of human sperm motility using compounds with reported phosphodiesterase inhibitor activity.</gtr:title><gtr:parentPublicationTitle>Human reproduction (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc401850ef0ea96a5d8e72fc9875ad81"><gtr:id>dc401850ef0ea96a5d8e72fc9875ad81</gtr:id><gtr:otherNames>Tardif S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0268-1161</gtr:issn><gtr:outcomeId>545b99733af598.54495137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56953E2D-C276-4ABA-88B5-8DF8504BE840</gtr:id><gtr:title>MR real-time tracking of hepatic motion during respiration in a Thiel Soft-fix cadaver</gtr:title><gtr:parentPublicationTitle>Biomedical Engineering / Biomedizinische Technik</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f29adc281998f6201874096ac71a77"><gtr:id>c9f29adc281998f6201874096ac71a77</gtr:id><gtr:otherNames>Cox B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>5463380d7a4b22.10716183</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C27BF2BE-6369-42AF-B4CD-9FFCBE33C7AF</gtr:id><gtr:title>P-018 MRI-based Endovascular Navigation in a Flow and Cadaveric Model; Feasibility Study</gtr:title><gtr:parentPublicationTitle>Journal of NeuroInterventional Surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/332b06de0b5a5466b965d08b0ade73b8"><gtr:id>332b06de0b5a5466b965d08b0ade73b8</gtr:id><gtr:otherNames>Buciuc R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54633454c3da84.63047464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0C66F42-B863-40D2-BC6A-E156716F45BD</gtr:id><gtr:title>Skin-targeted inhibition of PPAR ?/d by selective antagonists to treat PPAR ?/d-mediated psoriasis-like skin disease in vivo.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d1f6a27969d3f1b241ab20256f058a0"><gtr:id>1d1f6a27969d3f1b241ab20256f058a0</gtr:id><gtr:otherNames>Hack K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14237_27_22606335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA3FDAB7-2817-48E3-86D5-4F5364944E63</gtr:id><gtr:title>E-036 Cadaveric Flow Model for Endovascular Simulated Interventions</gtr:title><gtr:parentPublicationTitle>Journal of NeuroInterventional Surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f29adc281998f6201874096ac71a77"><gtr:id>c9f29adc281998f6201874096ac71a77</gtr:id><gtr:otherNames>Cox B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546331a7d74308.71713131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>908128C0-81DA-4722-9101-9EF2BD24F91C</gtr:id><gtr:title>Identification of small molecule inhibitors of pre-mRNA splicing.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd91d15e038f9c7ff7d9ba637dbb0d2f"><gtr:id>bd91d15e038f9c7ff7d9ba637dbb0d2f</gtr:id><gtr:otherNames>Pawellek A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>545b9973121202.15218744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23BC700A-DDF1-4A66-89CF-BD16DECE23FF</gtr:id><gtr:title>Discovery of ?2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor.</gtr:title><gtr:parentPublicationTitle>ACS medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f5fbd29076618385f6b5d6ffcbe6080"><gtr:id>4f5fbd29076618385f6b5d6ffcbe6080</gtr:id><gtr:otherNames>Aristotelous T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1948-5875</gtr:issn><gtr:outcomeId>G5QarkaeS8j</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>056AC50B-3E0A-45C3-A8B0-C65365CC0C49</gtr:id><gtr:title>MRI of Thiel-embalmed human cadavers.</gtr:title><gtr:parentPublicationTitle>Journal of magnetic resonance imaging : JMRI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d2f98e47c325124717076e537a14455"><gtr:id>6d2f98e47c325124717076e537a14455</gtr:id><gtr:otherNames>Gueorguieva MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1053-1807</gtr:issn><gtr:outcomeId>pm_14237_27_23818428</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G0900864</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>